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Introduction
After several randomized controlled trials (RCTs) failed to dem-
onstrate the superiority of endovascular treatment of stroke 
over medical management,1,2 the inclusion criteria of the next 
RCTs were narrowed, excluding patients with better natural 
history or poor prognostic factors at baseline, that could ham-
per the identification of the therapeutic effect of vessel revas-
cularization. These RCTs demonstrated the efficacy of mechan-
ical thrombectomy (MT) in patients with stroke due to large 
vessel occlusion in the anterior circulation.3 However, in clinical 
practice, a substantial proportion of patients do not fulfill 
these inclusion criteria.4 The Clinical Mismatch in the Triage of 
Wake Up and Late Presenting Strokes Undergoing Neurointer-
vention With Trevo (DAWN) trial and Endovascular Therapy 
Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE-3) 
(DAWN NCT02142283; DEFUSE-3 NCT02586415) RCTs extend-
ed the evidence for MT to the late time window using ad-
vanced imaging,5,6 but evidence for MT’s utility in other patient 
subgroups or without advanced imaging selection is lacking. 
Non-randomized reports7-9 and subgroup analysis of RCTs10 
suggest that the benefit of revascularization may be broader. 
Here, we estimated the efficacy of MT in patients with a vas-
cular occlusion within a population-based registry of stroke 
codes characterized by a broader clinical spectrum than pa-
tients enrolled in RCTs. Since this is a non-randomized study, 
we used an inverse probability of treatment weighting (IPTW) 
analysis from a propensity score (PS) in order to obtain a well-
balanced pseudo-population for baseline factors.
Methods
This observational study, conducted in accordance with STROBE 
guidelines (Supplementary Table 1), is based on the Codi Ictus 
Catalunya (CICAT) registry, a government-mandated, prospec-
tive, hospital-based dataset that includes all stroke code activa-
Background and Purpose In real-world practice, the benefit of mechanical thrombectomy (MT) is 
uncertain in stroke patients with very favorable or poor prognostic profiles at baseline. We studied 
the effectiveness of MT versus medical treatment stratifying by different baseline prognostic factors.
Methods Retrospective analysis of 2,588 patients with an ischemic stroke due to large vessel oc-
clusion nested in the population-based registry of stroke code activations in Catalonia from Janu-
ary 2017 to June 2019. The effect of MT on good functional outcome (modified Rankin Score ≤2) 
and survival at 3 months was studied using inverse probability of treatment weighting (IPTW) 
analysis in three pre-defined baseline prognostic groups: poor (if pre-stroke disability, age >85 
years, National Institutes of Health Stroke Scale [NIHSS] >25, time from onset >6 hours, Alber-
ta Stroke Program Early CT Score <6, proximal vertebrobasilar occlusion, supratherapeutic interna-
tional normalized ratio >3), good (if NIHSS <6 or distal occlusion, in the absence of poor prognos-
tic factors), or reference (not meeting other groups’ criteria). 
Results Patients receiving MT (n=1,996, 77%) were younger, had less pre-stroke disability, and re-
ceived systemic thrombolysis less frequently. These differences were balanced after the IPTW strat-
ified by prognosis. MT was associated with good functional outcome in the reference (odds ratio 
[OR], 2.9; 95% confidence interval [CI], 2.0 to 4.4), and especially in the poor baseline prognostic 
stratum (OR, 3.9; 95% CI, 2.6 to 5.9), but not in the good prognostic stratum. MT was associated 
with survival only in the poor prognostic stratum (OR, 2.6; 95% CI, 2.0 to 3.3).
Conclusions Despite their worse overall outcomes, the impact of thrombectomy over medical 
management was more substantial in patients with poorer baseline prognostic factors than pa-
tients with good prognostic factors.
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tions in Catalonia. We used data from consecutive patients in 
whom the stroke code was activated directly by the emergency 
medical services from January 2017 to June 2019. The following 
variables were registered: demographic information, vascular 
risk factors, pre-stroke functional status (modified Rankin Scale 
[mRS]), National Institutes of Health Stroke Scale (NIHSS) at 
admission, the presence of large vessel occlusion on admission, 
site of occlusion (proximal occlusion was defined as an intra-
cranial occlusion of the internal carotid, M1 portion of the mid-
dle cerebral artery, tandem occlusion, or basilar artery occlusion; 
distal occlusion was defined as an occlusion distal to M1 por-
tion of the middle cerebral artery, or in the anterior or posterior 
cerebral artery), revascularization treatment (none, systemic 
thrombolysis alone, MT with or without thrombolysis), and time 
metrics including time from onset to imaging and time to re-
vascularization treatment (systemic thrombolysis and MT). 
The impact of MT was studied in three pre-defined baseline 
prognostic groups defined around some of the main inclusion 
criteria of the pivotal RCTs that demonstrated the efficacy of 
MT in stroke, selected primarily for being well-established 
prognostic factors in stroke (not necessarily for potential inter-
actions with the effect of MT). Patients meeting these criteria 
were classified as the reference prognostic group (premorbid 
mRS ≤1, age ≤85 years, NIHSS ≤24 and ≥6, time from onset ≤6 
hours, Alberta Stroke Program Early CT Score [ASPECTS] ≥6,11 
proximal vascular occlusion in the anterior territory); patients 
not meeting at least one of the standard inclusion criteria were 
classified into poor (premorbid mRS >1, age >85 years, NIHSS 
≥25, time from onset >6 hours, large infarct with ASPECTS <6, 
proximal occlusion in the vertebrobasilar territory, suprathera-
peutic international normalized ratio >3), and good (if NIHSS 
<6 or distal occlusion in the anterior or posterior territory in 
the absence of any of the poor-prognosis features) prognostic 
groups. The primary outcome measures were centrally evaluat-
ed 3 months after the stroke and included functional outcome 
and vital status (good functional outcome defined as mRS ≤2, 
survival as mRS <6). The univariate distribution of the primary 
outcome measures was reported in each prognostic group ac-
cording to the treatment received. Symptomatic intracranial 
hemorrhage was defined according to the European Coopera-
tive Acute Stroke Study II (ECASS II) criteria.12 Successful re-
canalization following MT was defined as a grade 2b or 3 ac-
cording to the modified thrombolysis in cerebral ischemia 
scale.13 The ASPECTS score was not a mandatory variable in our 
registry but may have influenced treatment choice and was 
used for the study group assignment. For this reason, a sensi-
tivity analysis for the primary outcomes was conducted after 
multiple data imputations for missing values, including AS-
PECTS.
This is a Real-World Evidence (RWE) analysis using the pop-
ulation-based CICAT registry, which satisfies all legal require-
ments mandated by the local law of personal data protection. 
The dataset was processed and analyzed according to local and 
European laws: Regulation (EU) 2016/679 of the European Par-
liament and of the Council of April 27, 2016, on Data Protec-
tion and Spanish Organic Law 3/2018, of December 5, on Pro-
tection of Personal Data and guarantee of digital rights. The 
Ethical Committee at Hospital Clínic approved the study (regis-
try code HCB/2019/0716). Informed consent was waived be-
cause of the retrospective nature of the study.
Statistical analyses
Continuous variables were described as mean±standard devia-
tion or median with interquartile range (IQR), as appropriate. 
Categorical variables as absolute frequencies and percentages, 
or median with IQR for ordinal categorical variables. We used 
standardized differences, defined as differences between 
groups divided by pooled standard deviation, to assess hetero-
geneity between cohorts for baseline covariables.
To assess the impact of an intervention on the primary out-
comes in the absence of randomization, we used an IPTW anal-
ysis on PS suitable for multiple confounders in observational 
studies. The purpose of IPTW analysis is the creation of pseudo-
populations with low associations between treatment, con-
founders and indication bias. This methodological approach 
produces groups in which the treatment assignment is indepen-
dent of measured baseline covariates by weighting subjects by 
the inverse probability of treatment received.14,15 The estimation 
of the IPTW was performed calculating the PS from a logistic 
regression model to receive MT according to the variables de-
scribed in Table 1 and stabilized by the proportion of MT or 
medical treatment. IPTW-weighted logistic regression models 
were used to estimate the odds ratio (OR) and their 95% confi-
dence interval (CI) of good functional outcome and survival at 3 
months. These analyses were made for each prognosis stratum 
and included age, pre-stroke mRS, systemic thrombolysis, NIHSS 
score, and occlusion site. We checked for the adequate balance 
of baseline covariates after IPTW analyses in each prognostic 
stratum by calculating standardized differences, and a differ-
ence greater than ±0.20 represented a meaningful imbalance.16 
In this analysis, the maximum standardized difference was 
0.145, corresponding to baseline mRS for poor prognosis. 
The primary analysis did not include the ASPECT scale in 
IPTW calculation due to a high proportion of missing data 
(1,324 patients, 1,016 [49%] treated with MT, and 308 [48%] 
with medical management alone). A sensitivity analysis was 
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made, including the ASPECTS scale with missing data imputa-
tion to the previously described logistic regression model. We 
used the expectation-maximization algorithm,17 which relies 
on the flexible and reasonable missing at random assumption 
using age, sex, delay to radiological evaluation, NIHSS, mRS, 
comorbidities as hypertension, diabetes, dyslipidemia, atrial fi-
brillation, coronary heart disease, presence of a previous stroke, 
actual smoke, and presence of distal occlusion. 
We calculated the number needed to treat (NNT) for saving 
a patient from poor outcomes. NTT was estimated according to 
logistic regression models used in the primary analysis adapt-
ing the calculation proposed by Bender and Blettner18 and 
Bender et al.19 to present context by means: 
NNT = +
(OR - 1) × P0
1
(OR - 1) × (1 - P0)
OR
Where OR was estimated from IPTW-weighted logistic re-
gression models and P0 was the proportion of non-event.
In all statistical analyses, we applied a two-sided type I error of 
5%. SPSS version 25 (IBM Co., Armonk, NY, USA) and SAS version 
9.4 (SAS Institute Inc., Cary, NC, USA) were used for the analysis.
Results
Characteristics of the cohort
From 15,774 stroke code activations during the study period, 
10,117 had an ischemic stroke, and 3,989 had a vessel occlusion 
identified on initial imaging. After excluding patients with miss-
ing information, the analysis included 2,588 patients (Figure 1). 
Patients excluded from the analysis were younger and received 
systemic thrombolysis in a lower proportion than those included, 
but the other variables showed similar distribution according to 
the standard difference values (Supplementary Table 2). 
In the whole study cohort, 1,996 patients received MT and 
Table 1. Baseline characteristics of the treatment groups
Characteristic
Mechanical thrombectomy
No (n=592) Yes (n=1,996)
Age (yr) 75.0±13.3 71.0±13.6
Women 301 (51) 965 (48)
Pre-stroke mRS
≤1 416 (71) 1,682 (84)
>1 176 (29) 314 (16)
Systemic thrombolysis 423 (71) 917 (46)
Hypertension 398 (67) 1,222 (61)
Diabetes mellitus 131 (22) 384 (19)
Dyslipidemia 258 (44) 851 (43)
Atrial fibrillation 165 (28) 561 (28)
Coronary heart disease 100 (17) 280 (14)
Previous stroke/TIA 70 (12) 208 (10)
Smoking habit 60 (10) 283 (14)
NIHSS at admission 14 (7–20) 17 (11–21)
Delay to imaging (min) 158 (93–251) 162 (80–310)
ASPECTS 8 (6–10) 9 (8–10)
Occlusion site
M2, ACA, PCA 232 (39) 350 (18)
M1 196 (33) 1,009 (51)
TICA/Tandem 154 (26) 516 (26)
VB 10 (2) 121 (6)
Values are presented as mean±standard deviation, number (%), or median 
(interquartile range). Standard difference was considered acceptable if not 
greater than ±0.20.
mRS, modified Rankin Scale; TIA, transient ischemic attack; NIHSS, Nation-
al Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early 
CT Score; M2, second segment of the middle cerebral artery; ACA, anterior 
cerebral artery; PCA, posterior cerebral artery; M1, first segment of the 
middle cerebral artery; TICA, terminal internal carotid artery; VB, verte-
bro-basilar. 
Figure 1. Study selection process. The flow-diagram shows the patients in-
cluded in the analysis. TIA, transient ischemic attack; SAH, subarachnoid 
hemorrhage. *Missing values were vascular risk factors (hypertension, dia-
betes mellitus, dyslipidemia, atrial fibrillation, coronary heart disease, previ-
ous stroke/TIA, smoking habit variables) in 401 patients, delay to imaging in 
214, and occlusion site in 503.
15,774 Stroke code activations in Catalonia 
January 2017–June 2019
Patients without ischemic cause:
- 2,666 Stroke mimics
- 1,814 Intracerebral hemorrhage
- 947 TIA
- 230 SAH
10,117 Patients with acute ischemic stroke
- 6,292 Patients without vessel occlusion
3,989 Patients with a large vessel occlusion
2,588 Patients with available clinical data 
and functional status at 90 days
- 607 Patients with several missing data*
- 794 Patients lost to follow-up
1,996 Treated with mechanical thrombectomy 
(77%)
592 Not treated with mechanical thrombectomy 
(23%)
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592 medical management alone. Successful recanalization was 
achieved in 83% of patients treated with MT. Patients receiv-
ing MT were more likely to belong to the reference and poor 
category groups, were younger, had less pre-stroke disability, 
received systemic thrombolysis less frequently, and had better 
ASPECTS scores (Table 1). The pre-defined prognostic groups 
according to baseline characteristics included 976 patients 
(38%) in the reference group, 1,191 patients (46%) in the poor 
prognosis group, and 421 patients (16%) in the good prognosis 
group. The description of the prognostic factors determining 
group assignment is detailed in Supplementary Table 3.
Clinical outcome distributions without IPTW 
adjustment 
The functional status at 3 months in the study cohort accord-
ing to the treatment received in each prognostic group without 
IPTW adjustment are summarized in Figure 2. Any hemorrhage 
in follow-up imaging was more frequently found in patients 
treated with MT compared to those treated with only medical 
treatment in all prognosis subgroups (Table 2).
Primary outcome results: IPTW analysis 
The standard differences of the clinical and radiological vari-
ables at baseline between patients who received MT and those 
who received medical treatment alone were adequately bal-
anced after IPTW in the whole cohort (Figure 3) and stratified 
by prognostic groups (Supplementary Table 4). In the IPTW lo-
gistic regression model, MT was related to good outcomes in 
the subgroups of reference (OR, 2.94; 95% CI, 1.96 to 4.35; 
P<0.0001) and poor prognosis (OR, 3.85; 95% CI, 2.56 to 5.88; 
Table 2. Clinical course, radiological outcomes, and safety outcome measures
Outcome

















TICI 2b/3 1,658 (83) 198 (83) 700 (84) 760 (83)
Hemorrhagic 
  transformation
82 (14) 450 (23) 25 (14) 51 (21) 24 (17) 208 (25) 33 (12.18) 191 (21)
HI1 15 (3.8) 151 (9.4) 2 (1.5) 22 (11) 2 (2.2) 70 (10) 11 (6.63) 59 (8.0)
HI2 20 (5.0) 126 (7.8) 8 (5.8) 8 (4.2) 6 (6.5) 64 (9.3) 6 (3.61) 54 (7.4)
PH1 17 (4.3) 65 (4.0) 5 (3.6) 8 (4.2) 8 (8.6) 29 (4.2) 4 (2.41) 28 (3.8)
PH2 16 (4.0) 60 (3.7) 8 (5.8) 3 (1.6) 3 (3.2) 28 (4.1) 5 (3.01) 29 (4.0)
rPH 14 (3.5) 48 (3.0) 2 (1.5) 10 (5.2) 5 (5.4) 17 (2.5) 7 (4.22) 21 (2.9)
NIHSS at 24–36 hr 11 (4–20) 8 (3–18) 3 (1–9) 5 (1–12) 16 (6–20.5) 8 (3–16) 17 (8–21) 11 (3–20)
Values are presented as number (%) or median (interquartile range). 
MT, mechanical thrombectomy; TICI, thrombolysis in cerebral ischemia; HI1, hemorrhagic infarction type 1 (small petechiae along the margins of the infarct); 
HI2, hemorrhagic infarction type 2 (confluent petechiae within the infarcted area but no space-occupying effect); PH1, parenchymal hematoma (blood clots 
in ≤30% of the infarcted area with some slight space-occupying effect); PH2, parenchymal hematoma (blood clots in >30% of the infarcted area with a sub-
stantial space-occupying effect); rPH, remote parenchymal hematoma; NIHSS, National Institutes of Health Stroke Scale.
Figure 2. Primary outcome measures without inverse probability of treatment weighting adjustment. The Sankey diagram showing the treatment and out-
comes in each baseline prognostic category. MT, mechanical thrombectomy; mRS, modified Rankin Scale.
421 Good 240 MT
836 MT
1,035 mRS 0-2
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P<0.0001), but not in the good prognostic category (OR, 1.23; 
95% CI, 0.85 to 1.79; P=0.27). MT was associated with survival 
only in the poor prognosis category (OR, 2.56; 95% CI, 1.96 to 
3.33; P<0.001), more details are shown in Table 3 and Figure 4. 
Consequently, the NNT for good outcome was 4 (95% CI, 3 to 
7) in the reference prognosis group, 4 (95% CI, 2 to 5) in the 
poor prognosis group, and not interpretable because the CI 
does not include the NNT value in the good prognosis group 
(21; 95% CI, –41 to ∞ to 7). 
Sensitivity analysis
The sensitivity analyses after multiple data imputations con-
firmed the associations between MT and functional outcome. 
MT remained associated with good outcomes in the reference 
and poor baseline prognosis category groups. MT was associat-
ed with survival in the whole cohort of the sensitive analysis 
but did not reach signification when assessed for each prog-
nostic category (Table 3 and Figure 4). 
Discussion
This sizeable and representative population-based registry con-
firmed the benefit from MT in terms of functional outcome 
and survival in real-life practice, mainly in patients with non-
Table 3. Main and sensitivity analysis for outcome by logistic regression models with IPTW 
Primary outcome variables Percent (%)
Main analysis Sensitivity analysis
Logistic regression analyses (IPTW) 
Logistic regression analyses (IPTW)  
including ASPECTS (imputed values)
OR (95% CI) P NNT (95% CI) OR (95% CI) P NNT (95% CI)
Whole cohort
Good outcome 40 2.44 (1.96–2.94) <0.0001 5 (4 to 7) 1.82 (1.52–2.22) <0.0001 7 (5 to 10)
Survival 79 2.04 (1.67–2.5) <0.0001 11 (9 to 14) 1.33 (1.08–1.67) 0.009 23 (14 to 85)
Good prognostic group
Good outcome 59 1.23 (0.85–1.79) 0.270 21 (–41 to ∞ to 7) 1.28 (0.88–1.89) 0.207 18 (–41 to ∞ to 7)
Survival 90 0.69 (0.35–1.37) 0.293 26 (–34 to ∞ to 8) 0.65 (0.33–1.28) 0.218 22 (–34 to ∞ to 7)
Reference prognostic group
Good outcome 47 2.94 (1.96–4.35) <0.0001 4 (3 to 7) 2.78 (1.89–4.17) <0.0001 5 (3 to 7)
Survival 84 1.32 (0.83–2.08) 0.243 31 (–37 to ∞ to 12) 1.11 (0.68–1.82) 0.679 75 (–18 to ∞ to 14)
Poor prognostic group
Good outcome 28 3.85 (2.56–5.88) <0.0001 4 (2 to 5) 1.89 (1.35–2.7) 0.0002 8 (4 to 16)
Survival 70 2.56 (1.96–3.33) <0.001 7 (6 to 9) 1.27 (0.94–1.69) 0.121 22 (–80 to ∞ to 9)
IPTW, inverse probability of treatment weighting; ASPECTS, Alberta Stroke Program Early CT Score; OR, odd ratio; CI, confidence interval; NNT, number needed 
to treat.
Figure 3. Standardized differences before and after inverse probability of treatment weighting (IPTW). Standardized differences between mechanical thrombec-
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favorable prognostic factors at baseline. Consequently, it also 
suggested that the effect of MT was not homogenous in all 
patients with stroke and vessel occlusion, raising doubts on the 
efficacy of current revascularization techniques in patients 
with specific characteristics such as mild symptoms or distal 
occlusions. In contrast, patients with the poorest prognostic 
factors benefit substantially from MT.
The concerns about the external validity of the results gener-
ated in large RCTs addressing the efficacy of MT in large ves-
sels occlusions are emphasized by the finding that in this 
multi-center registry reflecting clinical practice in Catalonia, 
more than half of the patients treated with MT did not meet 
the main inclusion/exclusion criteria used in most of the stud-
ies that confirmed the efficacy of MT versus best medical 
treatment. These results are reassuring when dealing with such 
patients and raise the question of whether the efficacy of MT 
in certain subgroups of patients may be best tested in studies 
like this, rather than in randomized clinical trials that are 
sometimes unpractical and whose results may not be general-
ized to all patients. 
Figure 4. Primary outcome analysis. The forest plots illustrate the treatment effect in each group in terms of good functional outcome and survival in the 
main analysis (A) and in the sensitive analysis (B) after inverse probability of treatment weighting (IPTW) analysis. The sensitive IPTW analysis included the Al-
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Although the severity of the symptoms did not significantly 
modify MT’s effect in subgroup analyses of the thrombectomy 
RCTs,3 as usual in most designs of RCTs, included patients are 
relatively homogeneous, which induces a selection bias. In the 
end, the vast majority of patients in those trials had moderate 
to severe strokes. Our registry has good internal validity and 
confirms the findings of observational reports describing de-
creased MT benefits in patients with milder strokes.20-22 Overall, 
the evidence suggests that the risk of futile endovascular inter-
vention is highest in patients with low NIHSS at baseline or 
distal occlusions. It is expected that the results of the ongoing 
Minor Stroke Therapy Evaluation RCT (NCT03796468) will shed 
light on the efficacy of MT in patients with mild strokes. 
Inversely, patients included in the poor baseline prognostic 
stratum benefited as much as patients in the reference prog-
nostic stratum. This is in line with recent observations describ-
ing few complications and potential benefits of thrombectomy 
in groups of patients with large infarctions,7,10 or other poor 
prognostic factors such as poor collateral circulation8 and older 
age.23 At the same time, these results support the use of broad 
inclusion criteria in RCTs testing MT in stroke, as excluding pa-
tients with certain poor prognostic factors may paradoxically 
reduce the treatment’s effect size.24 Nevertheless, the overall 
clinical outcome is still poor in about two out of three patients 
of this subgroup of patients, meaning that they may benefit 
from better revascularization techniques, additional neuropro-
tectant strategies, or even improved imaging selection to iden-
tify extensive irreversible damage better. Although perfusion 
imaging is commonly used to select patients in the late time 
window in our population, technical parameters and operative 
criteria differed between centers, and quantitative data were 
not available in the registry.
The study has some limitations, primarily linked to its obser-
vational design, mainly the obvious prescription bias we tried 
to overcome with the IPTW statistical analysis technique. How-
ever, observational studies performed in large multicenter co-
horts are vital to confirm the real-life clinical impact of the ef-
fect of interventions proved to be beneficial in clinical trials. 
The assessment of the baseline ischemic lesion using ASPECTS 
was optional in the registry and was available only in half of 
the patients, not allowing us to include it in the calculation of 
the IPTW. However, in the sensitivity analysis using missing im-
putation for patients without the ASPECTS value, the effect of 
MT on functional outcome and survival was similar to that of 
the main analysis, despite a reduced effect in the poor prog-
nostic stratum (non-significant trend for survival), which re-
flects the prognostic value of ASPECTS. The evidence in favor 
of thrombectomy has gradually changed over time, and it 
could be argued that the definition of the groups in the study 
could be done differently. However, the objective of this analy-
sis was not to study the effect of each specific prognostic fac-
tor, but to compare the impact of MT across different prognos-
tic groups in a way that tries to minimize the influence of con-
founding factors. This is the main strength of the primary re-
sults of the study, stressing that the impact of MT is greater in 
patients with poorer overall prognosis.
Conclusions
This RWE analysis of a population-based registry reassures 
physicians considering MT for patients with poor prognostic 
indicators at baseline. Conversely, it suggests that extending 
the utility of MT to specific subgroups of patients with better 
natural history may require further research and technical ad-
vances. 
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Supplementary Table 1. STROBE statement—Checklist of items that should be included in reports of cohort studies 
Item no. Recommendation Page no.
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 1, 5
(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 7
Objectives 3 State specific objectives, including any prespecified hypotheses 7
Methods
Study design 4 Present key elements of study design early in the paper 8
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, 
and data collection
8
Participants 6 (a)  Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods 
of follow-up
8
(b)  For matched studies, give matching criteria and number of exposed and unexposed
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable
9
Data sources/measurement 8* For each variable of interest, give sources of data and details of methods of assessment (measurement) 
Describe comparability of assessment methods if there is more than one group
8
Bias 9 Describe any efforts to address potential sources of bias 7
Study size 10 Explain how the study size was arrived at 8
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings 
were chosen and why
8-9
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 10-12
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) If applicable, explain how loss to follow-up was addressed
(e) Describe any sensitivity analyses
Results
Participants 13* (a)  Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for 
eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
12-13
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
Descriptive data 14* (a)  Give characteristics of study participants (e.g., demographic, clinical, social) and information on 
exposures and potential confounders
13-14
(b) Indicate number of participants with missing data for each variable of interest
(c) Summarise follow-up time (e.g., average and total amount)
Outcome data 15* Report numbers of outcome events or summary measures over time 13
Main results 16 (a)  Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 
95% confidence interval). Make clear which confounders were adjusted for and why they were included
14
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses 17 Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses 14-15
Discussion
Key results 18 Summarise key results with reference to study objectives 15
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both 
direction and magnitude of any potential bias
17
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, 
results from similar studies, and other relevant evidence
15-16
Generalisability 21 Discuss the generalisability (external validity) of the study results 15
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 
original study on which the present article is based
18
An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. 
The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals 
of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://
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Supplementary Table 2. Baseline characteristics of the cohort included and excluded for the presence of missing data (except for ASPECTS) in the final 
analysis
Characteristic Patients excluded (n=607) Patients included (n=2,588) Standard difference
Age (yr) 74.9±13.7 71.9±13.6 –0.221
Women 298 (49) 1,266 (49) –0.004
Pre-stroke mRS –0.192
≤1 438 (72) 2,098 (81)
>1 169 (28) 490 (19)
Systemic thrombolysis 221 (36) 1,340 (52) 0.313
Hypertension 130 (64) 1,620 (63) –0.023
Diabetes mellitus 42 (21) 515 (20) –0.017
Dyslipidemia 79 (39) 1,109 (43) 0.084
Atrial fibrillation 58 (28) 726 (28) –0.008
Coronary heart disease 29 (14) 380 (15) 0.013
Previous stroke/TIA 13 (6) 278 (11) 0.156
Smoking habit 28 (14) 343 (13) –0.014
NIHSS at admission 17 (17–19) 16 (16–17) –0.013
Delay to imaging (min) 155 (138–194) 160 (153–169) –0.132
ASPECTS 8 (8–9) 9 (9–10) 0.345
Occlusion site 0.068
M2, ACA, PCA 0 (0) 582 (22)
M1 144 (27) 1,205 (47)
TICA‎/Tandem 220 (42) 670 (26)
VB 139 (26) 131 (5)
Values are presented as mean±standard deviation, number (%), or median (interquartile range). 
ASPECTS, Alberta Stroke Program Early CT score; mRS, modified Rankin Scale; TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale; 
M2, second segment of the middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery; M1, first segment of the middle cerebral ar-
tery; TICA, terminal internal carotid artery; VB, vertebro-basilar.
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Supplementary Table 3. Characterization of the factors determining the assignment of patients to poor or good prognosis categories
Variable Poor prognostic group Good prognostic group
Pre-stroke mRS >1 490 (41) 0 (0)
Age >85 years 334 (28) 0 (0)
Baseline NIHSS >25 85 (7) 0 (0)
Time from onset >6 hours 508 (43) 0 (0)
Vertebrobasilar occlusion 131 (11)
Supratherapeutic INR 20 (1.7)
Sum of poor prognostic factors
0 0 (0) 421 (100)
1 837 (70) 0 (0)
2 331 (28) 0 (0)
3 22 (1.8) 0 (0)
4 1 (0.1) 0 (0)
Baseline NIHSS <6 72 (6.1) 135 (32)
Distal occlusion 229 (19) 353 (84)
Sum of good prognostic factors
0 909 (76) 0 (0)
1 263 (22) 354 (84)
2 19 (1.6) 67 (16)
Values are presented as number (%).
mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; INR, international normalized ratio.






IPTW stratified by prognostic groups
Good (n=421) Reference (n=976) Poor (n=1,191)
Age –0.300 –0.020 0.039 0.035 –0.039
Women –0.050 0.010 –0.034 –0.061 0.060
Pre-stroke mRS –0.221 0.150 –0.120 0.028 0.145
Systemic thrombolysis –0.536 0.057 –0.001 0.089 –0.036
Hypertension –0.126 –0.036 –0.002 0.023 –0.083
Diabetes mellitus –0.071 –0.049 0.014 –0.132 –0.015
Dyslipidemia –0.019 0.019 –0.086 –0.039 –0.020
Atrial fibrillation 0.005 0.013 0.009 –0.043 –0.063
Coronary heart disease –0.079 –0.044 0.081 –0.001 0.025
Previous stroke/TIA –0.045 0.020 0.046 0.052 –0.002
Smoking habit 0.124 0.020 0.079 –0.029 0.103
NIHSS at admission 0.155 –0.013 0.013 –0.006 0.008
Delay to imaging 0.155 –0.013 0.013 –0.006 0.008
Occlusion site 0.352 –0.059 –0.066 0.141 0.003
IPTW, inverse probability of treatment weighting; mRS, modified Rankin Scale; TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke 
Scale.
